







an Open Access Journal by MDPI

Epigenetic Modifications in Cancer Development

Guest Editor:

Dr. Benoit Miotto

Institut Cochin, INSERM, U1016, CNRS, UMR8104, Université Paris Cité, 75014 Paris, France

Deadline for manuscript submissions:

24 May 2024

Message from the Guest Editor

Dear Colleagues,

It is now well known that epigenetic modifications (e.g., DNA methylation, histone modifications, histone variants, etc.) play a central role in cancer initiation and progression. These modifications regulate various essential cellular processes in cancer, including cell proliferation, apoptosis, invasion and migration. These modifications are also at the heart of cancer cell heterogeneity, cancer relapse and the emergence of treatment resistance. The characterization of these modifications, and of their functions, therefore enables us to improve patient diagnosis and envisage new therapeutic avenues. For this Special Issue, we welcome review articles and original research studies exploring these aspects.

Dr. Benoit Miotto *Guest Editor*













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us